OBJECTIVE: To identify cerebrospinal fluid (CSF) protein changes in persons who will develop familial Alzheimer disease (FAD) due to PSEN1 and APP mutations, using unbiased proteomics. DESIGN: We compared proteomic profiles of CSF from individuals with FAD who were mutation carriers (MCs) and related noncarriers (NCs). Abundant proteins were depleted and samples were analyzed using liquid chromatography-electrospray ionization-mass spectrometry on a high-resolution time-of-flight instrument. Tryptic peptides were identified by tandem mass spectrometry. Proteins differing in concentration between the MCs and NCs were identified. SETTING: A tertiary dementia referral center and a proteomic biomarker discovery laboratory. PARTICIPANTS: Fourteen FAD MCs (mean age, 34.2 years; 10 are asymptomatic, 12 have presenilin-1 [PSEN1 ] gene mutations, and 2 have amyloid precursor protein [APP ] gene mutations) and 5 related NCs (mean age, 37.6 years). RESULTS: Fifty-six proteins were identified, represented by multiple tryptic peptides showing significant differences between MCs and NCs (46 upregulated and 10 downregulated); 40 of these proteins differed when the analysis was restricted to asymptomatic individuals. Fourteen proteins have been reported in prior proteomic studies in late-onset AD, including amyloid precursor protein, transferrin, α(1)β-glycoprotein, complement components, afamin precursor, spondin 1, plasminogen, hemopexin, and neuronal pentraxin receptor. Many other proteins were unique to our study, including calsyntenin 3, AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) 4 glutamate receptor, CD99 antigen, di- N-acetyl-chitobiase, and secreted phosphoprotein 1. CONCLUSIONS: We found much overlap in CSF protein changes between individuals with presymptomatic and symptomatic FAD and those with late-onset AD. Our results are consistent with inflammation and synaptic loss early in FAD and suggest new presymptomatic biomarkers of potential usefulness in drug development.
OBJECTIVE: To identify cerebrospinal fluid (CSF) protein changes in persons who will develop familial Alzheimer disease (FAD) due to PSEN1 and APP mutations, using unbiased proteomics. DESIGN: We compared proteomic profiles of CSF from individuals with FAD who were mutation carriers (MCs) and related noncarriers (NCs). Abundant proteins were depleted and samples were analyzed using liquid chromatography-electrospray ionization-mass spectrometry on a high-resolution time-of-flight instrument. Tryptic peptides were identified by tandem mass spectrometry. Proteins differing in concentration between the MCs and NCs were identified. SETTING: A tertiary dementia referral center and a proteomic biomarker discovery laboratory. PARTICIPANTS: Fourteen FADMCs (mean age, 34.2 years; 10 are asymptomatic, 12 have presenilin-1 [PSEN1 ] gene mutations, and 2 have amyloid precursor protein [APP ] gene mutations) and 5 related NCs (mean age, 37.6 years). RESULTS: Fifty-six proteins were identified, represented by multiple tryptic peptides showing significant differences between MCs and NCs (46 upregulated and 10 downregulated); 40 of these proteins differed when the analysis was restricted to asymptomatic individuals. Fourteen proteins have been reported in prior proteomic studies in late-onset AD, including amyloid precursor protein, transferrin, α(1)β-glycoprotein, complement components, afamin precursor, spondin 1, plasminogen, hemopexin, and neuronal pentraxin receptor. Many other proteins were unique to our study, including calsyntenin 3, AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) 4 glutamate receptor, CD99 antigen, di- N-acetyl-chitobiase, and secreted phosphoprotein 1. CONCLUSIONS: We found much overlap in CSF protein changes between individuals with presymptomatic and symptomatic FAD and those with late-onset AD. Our results are consistent with inflammation and synaptic loss early in FAD and suggest new presymptomatic biomarkers of potential usefulness in drug development.
Authors: Jill Murrell; Bernardino Ghetti; Elizabeth Cochran; Miguel Angel Macias-Islas; Luis Medina; Arousiak Varpetian; Jeffrey L Cummings; Mario F Mendez; Claudia Kawas; Helena Chui; John M Ringman Journal: Neurogenetics Date: 2006-08-05 Impact factor: 2.660
Authors: Guanghui Wang; Wells W Wu; Trairak Pisitkun; Jason D Hoffert; Mark A Knepper; Rong-Fong Shen Journal: Anal Chem Date: 2006-08-15 Impact factor: 6.986
Authors: Jing Zhang; David R Goodlett; Elaine R Peskind; Joseph F Quinn; Yong Zhou; Qin Wang; Catherine Pan; Eugene Yi; Jimmy Eng; Ruedi H Aebersold; Thomas J Montine Journal: Neurobiol Aging Date: 2005-02 Impact factor: 4.673
Authors: Maja Puchades; Sara Folkesson Hansson; Carol L Nilsson; Niels Andreasen; Kaj Blennow; Pia Davidsson Journal: Brain Res Mol Brain Res Date: 2003-10-21
Authors: Jing Zhang; Izabela Sokal; Elaine R Peskind; Joseph F Quinn; Joseph Jankovic; Christopher Kenney; Kathryn A Chung; Steven P Millard; John G Nutt; Thomas J Montine Journal: Am J Clin Pathol Date: 2008-04 Impact factor: 2.493
Authors: John M Ringman; David Elashoff; Daniel H Geschwind; Brian T Welsh; Karen H Gylys; Cathy Lee; Jeffrey L Cummings; Greg M Cole Journal: Arch Neurol Date: 2012-06
Authors: Bing Bai; Chadwick M Hales; Ping-Chung Chen; Yair Gozal; Eric B Dammer; Jason J Fritz; Xusheng Wang; Qiangwei Xia; Duc M Duong; Craig Street; Gloria Cantero; Dongmei Cheng; Drew R Jones; Zhiping Wu; Yuxin Li; Ian Diner; Craig J Heilman; Howard D Rees; Hao Wu; Li Lin; Keith E Szulwach; Marla Gearing; Elliott J Mufson; David A Bennett; Thomas J Montine; Nicholas T Seyfried; Thomas S Wingo; Yi E Sun; Peng Jin; John Hanfelt; Donna M Willcock; Allan Levey; James J Lah; Junmin Peng Journal: Proc Natl Acad Sci U S A Date: 2013-09-10 Impact factor: 11.205